Open Label Study for the Use of Low Intensity Focused Ultrasound for Essential Tremor

Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18-90
SponsorUniversity of California, Los Angeles

About this trial

This open-label pilot study will evaluate the safety, tolerability, feasibility, and preliminary efficacy of repeated low-intensity focused ultrasound pulsation (LIFUP) targeting the ventral intermediate nucleus (Vim) of the thalamus in patients with Essential Tremor (ET). Twelve adults with clinically diagnosed ET will undergo six LIFUP treatment sessions over approximately two weeks using the BrainSonix BX Pulsar 1002 system. Tremor severity will be assessed using clinician-rated scales (TETRAS and FTM), patient-reported quality-of-life measures (QUEST), and objective accelerometry before and after treatment sessions, with additional follow-up visits at one and three months post-treatment. MRI scans will be performed at baseline and after the final treatment session to monitor safety. The study aims to characterize whether non-ablative focused ultrasound can safely and transiently modulate tremor-related thalamic circuits and provide preliminary evidence supporting future controlled trials of LIFUP for ET.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Confirmed clinical diagnosis of ET

Isolated tremor syndrome, at least 3 years duration

Subjective complaint of tremor assessed and validated by physician

Must be willing to comply with the study protocol

Disqualifiers

Severe microvascular disease or structural brain lesions equivalent to Fazekas scale of 3 or higher in the periventicular or deep white matter.

Subjects on blood thinning medications (e.g. Eliquis)

Recent stroke (within the last 6 months)

Implanted electrodes (e.g. DBS) in brain

Trial design

Design model

Single group

Treatments tested in this trial

  • Low Intensity Focused Ultrasound (LIFU)

    Device

    Participants will receive low-intensity focused ultrasound pulsation (LIFUP) delivered using the BrainSonix BX Pulsar 1002 investigational device targeting the ventral intermediate nucleus (Vim) of the thalamus.

Treatment groups

20 Participants
are divided into 1 treatment group
Group A: LIFU Open Label GroupExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Accelerometric Data of Tremor Severity

Accelerometric trackers will be used to quantify and track tremor severity at each study session.

Time frame
From enrollment until the end of treatment at 2 weeks

Secondary outcomes

1

TETRAS

The Essential Tremor Rating Scale is a clinically verified scale to track the severity of tremor.

Time frame
From enrollment to the end of treatment at 2 weeks.
2

Fahn-Tolosa-Marin Tremor Rating Scale

The Fahn-Tolosa-Marin Tremor Rating Scale is a clinically verified scale to track tremor severity.

Time frame
From enrollment to the end of treatment at 2 weeks.

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.